{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-301426","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2022-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.113207+00:00","generated_at":"2026-06-21T06:52:46.769713+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx and Kite (Gilead) partner on CART-ddBCMA; $225M upfront + $100M equity; 100% ORR in Phase 1","bullets":["Arcellx receives $225M upfront cash and $100M equity investment from Gilead; eligible for up to $3.9B in milestones.","Phase 1 trial: 100% ORR (38 pts), 71% CR/sCR, 80% CR/sCR in patients dosed >12 months ago; no Grade≥3 CRS at RP2D.","Kite to manufacture after tech transfer; 50/50 U.S. profit split; low-to-mid teen royalties ex-U.S.; deal expected to close Q1 2023.","Gilead purchases 3,478,261 shares at $100M; standstill and registration rights agreed.","iMMagine-1 Phase 2 pivotal trial initiated; Phase 1 trial of ACLX-002 for AML/MDS also started."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-301426","json":"https://secwatch.observer/filing/0001193125-22-301426.json","markdown":"https://secwatch.observer/filing/0001193125-22-301426.md","text":"https://secwatch.observer/filing/0001193125-22-301426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/d420020d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:52:46.769713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8159d8affa45e6d1d5ca83d98e68f862c98c9736","claim":"Arcellx, Inc. entered into Collaboration Agreement with Kite Pharma, Inc., a Gilead Company valued at $225 million upfront cash payment (effective 2022-12-09).","evidence_excerpt":"On December 9, 2022, Arcellx, Inc. (“Arcellx”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Kite Pharma, Inc., a Gilead Company (“Kite”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Kite Pharma, Inc., a Gilead Company"},{"label":"Value","value":"$225 million upfront cash payment"},{"label":"Effective","value":"2022-12-09"}],"fact_type":"material_agreement"},{"claim_id":"ab00c969e349c2b707fd4eb85b200e36b7a5637d","claim":"Arcellx, Inc. entered into Common Stock Purchase Agreement with Gilead Sciences, Inc. valued at $100 million (effective 2022-12-09).","evidence_excerpt":"pursuant to which Arcellx agreed to issue and sell, and Gilead has agreed to purchase, 3,478,261 shares of Arcelllx’s common stock (the “Shares”) for an aggregate purchase price of $100 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Value","value":"$100 million"},{"label":"Effective","value":"2022-12-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}